Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 389, Issue 4, 2016, Pages 369-379

  Behringer, Arnica ^a   Trappiel, Manuela ^b   Berghausen, Eva Maria ^a   Ten Freyhaus, Henrik ^a   Wellnhofer, Ernst ^c   Odenthal, Margarete ^a   Blaschke, Florian ^b   Er, Fikret ^d   Gassanov, Natig ^d   Rosenkranz, Stephan ^a   Baldus, Stephan ^a   Kappert, Kai ^b   Caglayan, Evren ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d Klinik für Anästhesiologie Intensiv Notfall und Schmerzmedizin   (Germany)

Author keywords

Monocrotaline; PPAR; Pulmonary hypertension; Rat; Right ventricle

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COLLAGEN; MONOCROTALINE; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CARDIOVASCULAR AGENT; SPP1 PROTEIN, RAT;

AIRWAY REMODELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART INJURY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE HYPERTROPHY; INFLAMMATION; INSULIN RESISTANCE; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; LUNG PARENCHYMA; MACROPHAGE; MALE; MONOCROTALINE-INDUCED PULMONARY HYPERTENSION; NONHUMAN; ORGAN WEIGHT; PROTEIN EXPRESSION; PULMONARY ARTERY; RAT; SURVIVAL RATE; VASCULAR REMODELING; AGONISTS; ANIMAL; ARTERIAL PRESSURE; CARDIAC MUSCLE CELL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE; HEART VENTRICLE REMODELING; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG ALVEOLUS MACROPHAGE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ARTERIAL PRESSURE; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; FIBROSIS; HEART VENTRICLES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MACROPHAGES, ALVEOLAR; MALE; MONOCROTALINE; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; OSTEOPONTIN; PPAR GAMMA; PULMONARY ARTERY; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; VASCULAR REMODELING; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 84960809729     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-015-1205-3     Document Type: Article

References (38)

1. Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, Wick M, Nemenoff RA, Geraci MW, Voelkel NF (2003) Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 92:1162-1169
2. Caglayan E, Blaschke F, Takata Y, Hsueh WA (2005) Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways. Curr Opin Pharmacol 5:135-142
3. Caglayan E, Stauber B, Collins AR, Lyon CJ, Yin F, Liu J, Rosenkranz S, Erdmann E, Peterson LE, Ross RS, Tangirala RK, Hsueh WA (2008) Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes 57:2470-2479
4. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ (2007) Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 292:L885-L897
5. Dias-Neto M, Luisa-Neves A, Pinho S, Goncalves N, Mendes M, Eloy C, Lopes JM, Goncalves D, Ferreira-Pinto M, Leite-Moreira AF, Henriques-Coelho T (2015) Pathophysiology of infantile pulmonary arterial hypertension induced by monocrotaline. Pediatr Cardiol 36:1000-1013
6. Dickinson MG, Kowalski PS, Bartelds B, Borgdorff MA, van der Feen D, Sietsma H, Molema G, Kamps JA, Berger RM (2014) A critical role for Egr-1 during vascular remodelling in pulmonary arterial hypertension. Cardiovasc Res 103:573-584
7. Gao M, Jiang Y, Xiao X, Peng Y, Yang M (2015) Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model. J Surg Res 195:550-558
8. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tuder RM, Voelkel NF (2001) Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 88:555-562
9. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M (2007) Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 115:1275-1284
10. Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, Rabinovitch M (2008) An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 118:1846-1857
11. Hou X, Hu Z, Huang X, Chen Y, He X, Xu H, Wang N (2014) Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients. J Mol Med (Berl) 92:487-495
12. Hsueh WA, Jackson S, Law RE (2001) Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 24:392-397
13. Kim EK, Lee JH, Oh YM, Lee YS, Lee SD (2010) Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats. Respirology 15:659-668
14. Kozlowska H, Baranowska-Kuczko M, Schlicker E, Kozlowski M, Kloza M, Malinowska B (2013) Relaxation of human pulmonary arteries by PPARgamma agonists. Naunyn Schmiedeberg's Arch Pharmacol 386:445-453
15. Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT (2014) Pulmonary arterial hypertension: the clinical syndrome. Circ Res 115:115-130
16. Lee CH, Olson P, Evans RM (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144:2201-2207
17. Li M, Li Z, Sun X, Yang L, Fang P, Liu Y, Li W, Xu J, Lu J, Xie M, Zhang D (2010) Heme oxygenase-1/p21WAF1 mediates peroxisome proliferator-activated receptor-gamma signaling inhibition of proliferation of rat pulmonary artery smooth muscle cells. FEBS J 277:1543-1550
18. Mam V, Tanbe AF, Vitali SH, Arons E, Christou HA, Khalil RA (2010) Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther 332:455-462
19. Matsuda Y, Hoshikawa Y, Ameshima S, Suzuki S, Okada Y, Tabata T, Sugawara T, Matsumura Y, Kondo T (2005) Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki Gakkai Zasshi 43:283-288
20. Matsuura N, Asano C, Nagasawa K, Ito S, Sano Y, Minagawa Y, Yamada Y, Hattori T, Watanabe S, Murohara T, Nagata K (2015) Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome. Int J Cardiol 179:360-369
21. Michelakis ED (2014) Pulmonary arterial hypertension: yesterday, today, tomorrow. Circ Res 115:109-114
22. Michelakis ED, Wilkins MR, Rabinovitch M (2008) Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 118:1486-1495
23. Nisbet RE, Bland JM, Kleinhenz DJ, Mitchell PO, Walp ER, Sutliff RL, Hart CM (2010) Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol 42:482-490
24. Ota D, Kanayama M, Matsui Y, Ito K, Maeda N, Kutomi G, Hirata K, Torigoe T, Sato N, Takaoka A, Chambers AF, Morimoto J, Uede T (2014) Tumor-alpha9beta1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts. J Mol Med (Berl) 92:1271-1281
25. Oyama Y, Akuzawa N, Nagai R, Kurabayashi M (2002) PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. Circ Res 90:348-355
26. Palazzuoli A, Ruocco G, Cekorja B, Pellegrini M, Del Castillo G, Nuti R (2015) Combined BNP and echocardiographic assessment in interstitial lung disease for pulmonary hypertension detection. Int J Cardiol 178:34-36
27. Paulin R, Michelakis ED (2014) The metabolic theory of pulmonary arterial hypertension. Circ Res 115:148-164
28. Rabinovitch M (2008) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118:2372-2379
29. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR (2014) Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 115:165-175
30. Rangwala SM, Lazar MA (2004) Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25:331-336
31. Ryan J, Dasgupta A, Huston J, Chen KH, Archer SL (2015) Mitochondrial dynamics in pulmonary arterial hypertension. J Mol Med (Berl) 93:229-242
32. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811-2821
33. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297:L1013-L1032
34. Tachibana H, Ogawa D, Matsushita Y, Bruemmer D, Wada J, Teshigawara S, Eguchi J, Sato-Horiguchi C, Uchida HA, Shikata K, Makino H (2012) Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy. J Am Soc Nephrol 23:1835-1846
35. ten Freyhaus H, Dumitrescu D, Schnorbach S, Kappert K, Viethen T, Hellmich M, Hunzelmann N, Rosenkranz S (2015) CT-proET1 predicts pulmonary hemodynamics in scleroderma-associated pulmonary hypertension. Clin Res Cardiol 104:525-529
36. Walker LA, Walker JS, Glazier A, Brown DR, Stenmark KR, Buttrick PM (2011) Biochemical and myofilament responses of the right ventricle to severe pulmonary hypertension. Am J Physiol Heart Circ Physiol 301:H832-H840
37. Yuan JX, Rubin LJ (2005) Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 111:534-538
38. Zaitone SA, Barakat BM, Bilasy SE, Fawzy MS, Abdelaziz EZ, Farag NE (2015) Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. Naunyn Schmiedeberg's Arch Pharmacol 388:587-600